NEW DELHI : Combination of casirivimab and imdevimab―two monoclonal antibody treatments—keep high-risk patients out of the hospital when infected with mild to moderate covid-19, a study published in The Lancet's EClinicalMedicine has showed.
The observational study was done by researchers of Mayo Clinic, a non-profit organization working on innovation in clinical practice, education and research.
Monoclonal antibodies are also prescribed in India. Nearly 1,400 Mayo Clinic patients were enrolled in the study; 696 of them received the drug combo between December 2020 and early April, while an equal matched cohort did not receive it.